The outlook for the UK economy remains flat and innovative small- and medium-sized enterprises (SMEs) continue to face a squeeze on funding, says the UK BioIndustry Association (BIA), which today publishes a new report detailing a scheme to enable the British public to support the innovative businesses that will drive the nation's future economic growth.
In the report, titled Citizens' Innovation Funds - Engaging the public with UK innovation, new figures estimate that £300 million ($476.5 million) of investment could be unlocked a year from the scheme creating over 1,500 new jobs in the knowledge economy.
The introduction of Citizens' Innovation Funds (CIFs), which are a tax-advantaged investment scheme, would unleash the patriotic potential of the general public by offering an opportunity to invest in innovative UK companies, says the BIA. The CIF concept is based on the successful French scheme - Fonds Communs de Placements dans l'Innovation (FCPI) - which has raised over 6 billion euros ($7.56 billion) since 1997 and invested in more than 1,000 innovative companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze